IQVIA Holdings (IQV) executive Staub received 26,088 Stock Appreciation Right
Stocks in this Quantisnow insightHealth Care
Insider transactions reported
W Richard Staub (executive at IQVIA Holdings Inc., IQV) reported that they received 26,088 Stock Appreciation Right on Feb 9, 2026.
- Reporting person
- Staub W Richard
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Feb 9, 2026 | Grant or award (A) | Stock Appreciation RightOn 26,088 Common Stock1 | +26,088 | - | - | 26,088 direct |
Holdings before and after
- Stock Appreciation Right: 0 to 26,088 direct
Footnotes from the filing
- 1. This stock appreciation right vests in three annual installments beginning on February 9, 2027.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Staub report in this IQV Form 4?
W Richard Staub (executive at IQVIA Holdings Inc., IQV) reported that they received 26,088 Stock Appreciation Right on Feb 9, 2026.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for IQV
Across the 12 sessions after earlier IQV headlines, the stock closed higher 3 times and lower 9 times, with a median move of 1.2% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | IQV | SPY |
|---|---|---|---|
| Feb 10, 2026 | IQVIA and Duke Clinical Research Institute Announce Strategic Collaboration to Advance Clinical Research in Obesity and Related Conditions | -5.3% | -0.3% |
| Feb 5, 2026 | IQVIA Reports Fourth-Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance | -10.7% | -1.2% |
| Jan 29, 2026 | IQVIA and Boehringer Ingelheim announce strategic long-term global commercial data foundation transformation collaboration | -1.7% | -0.2% |
| Jan 23, 2026 | IQVIA Named to the Fortune® World's Most Admired Companies™ List, Ranked No. 1 in Its Sector for Fifth Consecutive Year | -1.6% | +0.0% |
| Jan 21, 2026 | IQVIA to Announce Fourth-Quarter and Full-Year 2025 Results on February 5, 2026 | +3.3% | +1.2% |
| Dec 2, 2025 | Morgan Stanley resumed coverage on IQVIA with a new price targetand 1 other headline that session | -1.2% | +0.2% |
Earlier insider filings at IQV
- Feb 11, 2026SEC Form 4 filed by Officer Sherbet Eric
- Feb 11, 2026SEC Form 4 filed by Officer Patel Bhavik
- Feb 11, 2026SEC Form 4 filed by Officer Haas Bernd
- Feb 11, 2026SEC Form 4 filed by Officer Grenfell Alistair
- Feb 11, 2026SEC Form 4 filed by Officer Fedock Michael J.
Keep researching IQV
- IQV insider tradesEvery buy and sale reported by IQVIA Holdings Inc. officers, directors and large holders.
- What is Form 4?The SEC filing that reports a change in an insider's holdings, such as a purchase, sale, option exercise or grant, generally within two business days.
- Form 4 explainedForm 4 is the SEC filing that discloses when officers, directors and 10% owners buy or sell company stock, due within 2 business days. Learn every key field and code.
- Insider trading trackerThe latest insider buys and sales across every stock.
- IQV earnings historyPast IQVIA Holdings Inc. earnings releases, newest first.
- IQV financial statementsRevenue, profit, cash flow and balance sheet from IQVIA Holdings Inc.'s SEC filings.
Quantisnow market dataNYSE
IQV
IQVIA Holdings Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Listed since
- 2013
Get push alerts for IQV
Full IQV profile on Quantisnow Follow IQV and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time